Erasca Inc
Suletud
12.02 -9.49
Ülevaade
Aktsiahinna muutus
24h
Min
11.8
Max
13.1
Sissetulek | -154M -183M |
|---|---|
Aktsiakasum | -0.6 |
Töötajad | 103 |
EBITDA | -5.3M -37M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +58.65% upside |
Järgmine tulemuste avaldamine | 10. aug 2026 |
|---|
Turukapital | 1.1B 4.3B |
|---|---|
Eelmine avamishind | 21.51 |
Eelmine sulgemishind | 12.02 |
Erasca Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Erasca Inc Prognoos
Hinnasiht
By TipRanks
58.65% tõus
12 kuu keskmine prognoos
Keskmine 20.91 USD 58.65%
Kõrge 30 USD
Madal 12 USD
Põhineb 11 Wall Streeti analüütiku instrumendi Erasca Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
